Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 2;24(9):e202300068.
doi: 10.1002/cbic.202300068. Epub 2023 Apr 4.

Oligonucleotides Containing C5-Propynyl Modified Arabinonucleic Acids: Synthesis, Biophysical and Antisense Properties

Affiliations

Oligonucleotides Containing C5-Propynyl Modified Arabinonucleic Acids: Synthesis, Biophysical and Antisense Properties

Alexander Pontarelli et al. Chembiochem. .

Abstract

The introduction of chemical modifications on the nucleic acid scaffold has allowed for the progress of antisense oligonucleotides (ASOs) in the clinic for the treatment of a variety of disorders. In contribution to the repertoire of gene-silencing nucleic acid modifications, herein we report the synthesis and incorporation of C5-propynyl arabinouridine (araUP ) and arabinocytidine (araCP ) into mixed-base ASOs containing a pyrimidine core. Substitution of the core with araUP and araCP resulted in stabilization of the duplex formed with RNA but not with DNA. Similar results were obtained with ASOs bearing phosphorothioate linkages or methoxyethyl (MOE) wings in a gapmer design. All modified ASOs were compatible with E. coli RNase H mediated degradation of target RNA. Substitution of DNA for araUP and araCP in the central portion of a gapmer with MOE wings demonstrated improved nuclease resistance. These results suggest C5-modified arabinonucleic acids may serve as a potential chemical modification for therapeutic ASOs.

Keywords: E. coli RNase H; antisense therapy; arabinonucleic acids; nucleoside synthesis; oligonucleotide synthesis.

PubMed Disclaimer

References

    1. J. A. Kulkarni, D. Witzigmann, S. B. Thomson, S. Chen, B. R. Leavitt, P. R. Cullis, R. van der Meel, Nat. Nanotechnol. 2021, 16, 630-643.
    1. J. Lieberman, Nat. Struct. Mol. Biol. 2018, 25, 357-364.
    1. S. T. Crooke, B. F. Baker, R. M. Crooke, X. H. Liang, Nat. Rev. Drug Discovery 2021, 20, 427-453.
    1. S. T. Crooke, X. H. Liang, B. F. Baker, R. M. Crooke, J. Biol. Chem. 2021, 296, 100416.
    1. A. Khvorova, J. K. Watts, Nat. Biotechnol. 2017, 35, 238-248.

Publication types

LinkOut - more resources